Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04063267 · ClinicalTrials.gov registry record · Phase 2
Electronic Cigarettes as a Harm Reduction Strategy in Individuals With Substance Use Disorder
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT04063267 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 48 participants.
The verdict
NCT04063267, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
Patients in addiction treatment have exceptionally higher rate of cigarette smoking and very low quit rates compared to the general population. The purpose of this study is to examine the feasibility of using e-cigarettes as a method for harm reduction and the effects of providing e-cigarettes (or placebo e-cigarettes) on smoking outcomes among patients in addiction treatment.
Interventions
- OTHER Nicotine Replacement Therapy
- OTHER E cigarettes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-10-27 |
| Est. Completion | 2024-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04063267
The ClinicalTrials.gov registry entry for NCT04063267 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nicotine Replacement Therapy is the first listed.
NCT04063267 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04063267 about?
NCT04063267 is a clinical study titled "Electronic Cigarettes as a Harm Reduction Strategy in Individuals With Substance Use Disorder". Patients in addiction treatment have exceptionally higher rate of cigarette smoking and very low quit rates compared to the general population. The purpose of this study is to examine the feasibility of using e-cigarettes as a method for harm reduction and the effects of providing e-cigarettes (or p...
What is the current status of trial NCT04063267?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-10-27. Estimated completion is 2024-06-30.
What interventions are being tested in trial NCT04063267?
The interventions under investigation include: Nicotine Replacement Therapy (OTHER), E cigarettes (OTHER).
Who is sponsoring clinical trial NCT04063267?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.